Sign In  |  Register  |  About Mill Valley  |  Contact Us

Mill Valley, CA
September 01, 2020 1:29pm
7-Day Forecast | Traffic

  • Search Hotels in Mill Valley

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Deciphera Pharmaceuticals, Inc. - Common Stock (NQ: DCPH )

25.59 UNCHANGED
Last Price Updated: 4:00 PM EDT, Jun 10, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Deciphera Pharmaceuticals, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 Next >
The Week Ahead In Biotech (Feb. 6-12): Pfizer, AstraZeneca Earnings, Conference Presentations, IPOs And More
Biotech stocks managed to close the week ending Feb. 4 with gains. Stocks recovered along with the broader markets early in the week, but came under pressure midweek amid negative reaction to some big... 
Via Benzinga
Deciphera Pharmaceuticals, Inc. to Present at Upcoming Investor Conferences
From Deciphera Pharmaceuticals, Inc.
Via Business Wire
Deciphera Pharmaceuticals to Announce Fourth Quarter and Full Year 2021 Financial Results and Host Conference Call and Webcast on February 8, 2022
From Deciphera Pharmaceuticals, Inc.
Via Business Wire
Deciphera Pharmaceuticals Presents Results from the INTRIGUE Phase 3 Clinical Study at the American Society of Clinical Oncology Plenary Series Session
From Deciphera Pharmaceuticals, Inc.
Via Business Wire
The Week Ahead In Biotech (Jan. 23-29): Roche, Azurity FDA Decisions, J&J, Vertex Earnings, & More
Biotech stocks pulled back yet again during the week ending Jan. 21, with the sector retreating along with the broader market. The news flow tapered off following the frenetic pace of the week that... 
Via Talk Markets
The Week Ahead In Biotech (Jan 23-29): Roche, Azurity FDA Decisions, J&J, Vertex Earnings, Samsara Vision IPO And More
Biotech stocks pulled back yet again during the week ending Jan. 21, with the sector retreating along with the broader market. The news flow tapered off following the... 
Via Benzinga
Deciphera Pharmaceuticals Provides Corporate Update and Highlights Key 2022 Corporate Milestones
From Deciphera Pharmaceuticals, Inc.
Via Business Wire
Deciphera Pharmaceuticals, Inc. to Present at the 40th Annual J.P. Morgan Healthcare Conference
From Deciphera Pharmaceuticals, Inc.
Via Business Wire
Deciphera Announces Approval of QINLOCK® in the United Kingdom for the Treatment of Fourth-Line Gastrointestinal Stromal Tumor
From Deciphera Pharmaceuticals, Inc.
Via Business Wire
Deciphera: Why There Won’t Be a Quick Recovery
It will take awhile for DCPH stock to recover after major clinical setback 
Via InvestorPlace
691 Stocks Are Down Over 50% This Year
It may be hard to believe because the stock market has been in such an uptrend this year, but there are some interesting statistics for stock performance year-to-date. 
Via Talk Markets
Why Deciphera Pharmaceuticals Shot 12% Higher Today
The company announced a comprehensive restructuring program. 
Via The Motley Fool
Deciphera Pharmaceuticals Is Trying to Beat Financial Cancer — And Losing Hard
Deciphera is a biotech full of hope but lagging on financial performance. The recent selloff in DCPH stock is justified by its poor trials. 
Via InvestorPlace
Deciphera Pharma Stock Rises After Announcing Corporate Restructuring
Deciphera Pharmaceuticals Inc (NASDAQ: DCPH) will undergo a corporate restructuring to eliminate 35% of its workforce and end a Phase 1/2 program for solid tumors... 
Via Benzinga
Don’t Bet on a Deciphera Stock Comeback
Investors weren't wrong in dumping DCPH stock after terrible top-line results for the biotech company's flagship candidate. Avoid for now. 
Via InvestorPlace
Deciphera Pharmaceuticals Announces Restructuring to Prioritize Clinical Development Programs and Streamline Commercial Operations
From Deciphera Pharmaceuticals
Via Business Wire
Deciphera's Qinlock Approved In Europe For Gastric Cancer
The European Commission has approved Deciphera Pharmaceuticals Inc's (NASDAQ: DCPH) Qinlock (ripretinib)for adult patients with advanced gastrointestinal... 
Via Benzinga
Deciphera Receives European Commission Approval of QINLOCK® for the Treatment of Fourth-Line Gastrointestinal Stromal Tumor
From Deciphera Pharmaceuticals, Inc.
Via Business Wire
Take a Bearish Stance on Bruised and Battered Deciphera Pharmaceuticals
Unfavorable clinical results and a wide earnings miss will undoubtedly sink DCPH stock. Resist the temptation to buy the dip. 
Via InvestorPlace
Topics Earnings
Exposures Financial
What 6 Analyst Ratings Have To Say About Deciphera Pharmaceuticals
Analysts have provided the following ratings for Deciphera Pharmaceuticals (NASDAQ: 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For November 8, 2021
Upgrades For Nektar Therapeutics (NASDAQ: 
Via Benzinga
10 Biggest Price Target Changes For Monday
Barclays cut Deciphera Pharmaceuticals, Inc. (NASDAQ: 
Via Benzinga
Mid-Afternoon Market Update: Dow Surges 200 Points; Grid Dynamics Shares Spike Higher
Toward the end of trading Friday, the Dow traded up 0.57% to 36,331.86 while the NASDAQ rose 0.20% to 15,972.41. The S&P also rose, gaining 0.40% to 4,698.70. The U.S. has the... 
Via Benzinga
Topics Stocks
Exposures US Equities
DCPH Stock Alert: Why Is Deciphera Pharmaceuticals Plunging 70%?
Today, investors in Deciphera Pharmaceuticals and DCPH stock have seen tremendous selling pressure take this stock to all-time lows. 
Via InvestorPlace
12 Health Care Stocks Moving In Friday's Intraday Session
Gainers Chinook Therapeutics (NASDAQ:KDNY) shares increased by 28.75% to $15.76 during Friday's regular session. Trading volume for this security as of 12:30 EST is 1.... 
Via Benzinga
92 Biggest Movers From Friday
Gainers Mainz Biomed B.V. (NASDAQ: MYNZ) shares jumped 99.8% to close at $9.99 on Friday. Mainz Biomed priced its initial public offering of 2 million ordinary shares at $5, the... 
Via Benzinga
Mid-Day Market Update: Gold Rises 1%; Deciphera Pharmaceuticals Shares Plummet
Midway through trading Friday, the Dow traded up 0.65% to 36,358.13 while the NASDAQ rose 0.48% to 16,016.51. The S&P also rose, gaining 0.58% to 4,707.33. The U.S. has the... 
Via Benzinga
Topics Stocks
Exposures US Equities
64 Stocks Moving In Friday's Mid-Day Session
Gainers Mainz Biomed B.V. (NASDAQ: MYNZ) shares climbed 198.4% to $14.92. Mainz Biomed priced its initial public offering of 2 million ordinary shares at $5, the middle of the... 
Via Benzinga
Mid-Morning Market Update: Markets Open Higher; US Economy Adds 531,000 Jobs
Following the market opening Friday, the Dow traded up 0.84% to 36,429.04 while the NASDAQ rose 0.68% to 16,049.24. The S&P also rose, gaining 0.74% to 4,714.85. The U.S. has... 
Via Benzinga
Topics Economy Stocks
Exposures Economy US Equities
Why Did Deciphera Stock Plunged 70% Today?
Deciphera Pharmaceuticals Inc (NASDAQ: DCPH) stock plunged to a 52-week after announcing disappointing results from the INTRIGUE Phase 3 study of Qinlock in... 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Copyright © 2010-2020 MillValley.com & California Media Partners, LLC. All rights reserved.